<DOC>
	<DOCNO>NCT00478634</DOCNO>
	<brief_summary>This study ass safety RAD001 give together cetuximab irinotecan</brief_summary>
	<brief_title>A Phase 1 Study Investigating Combination RAD001 , Cetuximab Irinotecan Second-line Therapy After FOLFOX ( XELOX ) Plus Bevacizumab Patients With Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Inclusion criterion : Age ≥ 18 year old ≤ 65 year old . Patients metastatic CRC . Confirmation CRC diagnosis histological cytological specimen original resection primary tumor . Patients progress despite prior therapy FOLFOX ( 5FU oxaliplatin ) plus bevacizumab XELOX ( capecitabine oxaliplatin ) plus bevacizumab . Patients least one measurable lesion RECIST determine Computer Tomography ( CT ) Scan , Magnetic Resonance Imaging ( MRI ) physical examination . Patients WHO performance status 0 1 . Exclusion criterion : Patients Gilbert 's syndrome syndrome associate deficient glucoronidation bilirubin . Patients homozygous UGT1A1*28 allele determine sequence . Patients receive previous irinotecanbased therapy . Prior treatment mTOR inhibitor . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Colorectal Cancer</keyword>
	<keyword>Colorectal Carcinoma</keyword>
	<keyword>Colorectal Tumors</keyword>
	<keyword>Neoplasms , Colorectal</keyword>
</DOC>